Web21 okt. 2024 · A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Web20 apr. 2011 · IR induces overexpression and activity of the MET oncogene through the ATM-NF-κB signaling pathway; MET, in turn, promotes cell invasion and protects cells …
The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses …
Web20 feb. 2024 · The main purpose of this study is to determine the potential inhibitory/inducing effects of JNJ-54175446 after single and repeated dosing on the single-dose pharmacokinetics (PK) of a cocktail, containing selective probes of cytochrome P450 (CYP) enzymes (CYP3A4/A5, CYP2C9, CYP1A2, CYP2D6, CYP2B6, and CYP2C19) in … WebA modest reduction in alertness was observed at 150-225 mg doses, JNJ-40411813 (500 mg) reduced S (+) ketamine-induced negative symptoms by approximately 43% and 30% in cohorts 1 and 3, respectively. JNJ-40411813 was generally well-tolerated. Trial registration: ClinicalTrials.gov NCT01101659 . linking screen to laptop
European Commission Approves VELCADE® As A Frontline …
Web22 mrt. 2024 · Investing.com - J&J (NYSE: JNJ) rapporteerde op dinsdag voor het vierde kwartaal een winst die hoger is dan verwacht en een omzet die achterblijft bij de voorspellingen. Het... Het Amerikaanse... Web10 okt. 2024 · SPRING HOUSE, PENNSYLVANIA, October 10, 2024 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an … Web5 mei 2024 · The goal: invite nurses across the U.S. to submit their ideas for forward-thinking medical devices, health technologies, protocols and even treatment approaches. … houlihans wireless